Crossref
Phase III ATTR-CM Trials: Rethinking the “Placebo” Arm
Circulation · 10.03.2026 · 153 (10) · 693-695
DOI: 10.1161/circulationaha.125.078409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 10.03.2026. Verfasst von Vincent Algalarrondo und 1 weiteren Autor:innen. Beteiligte Einrichtung: CRMR Ceramic-Cardio, Cardiology Department, Bichat Hospital, Paris, France (V.A., M.S.S.). Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
amyloidosisamyloidosis, hereditary, transthyretin-relatedclinical trial
Autor:innen und Institutionen
- CRMR Ceramic-Cardio, Cardiology Department, Bichat Hospital, Paris, France (V.A., M.S.S.).
- Université Paris Cité, France (V.A.).
- F-CRIN GRACE: French Clinical Research Infrastructure Network-Group for Research on Amyloidosis, France (V.A.).
ORCID-Profile: Vincent Algalarrondo, Michel S Slama
Zitieren
APA
Algalarrondo, V., & Slama, M. S. (2026). Phase III ATTR-CM Trials: Rethinking the “Placebo” Arm. Circulation, 153(10), 693-695. https://doi.org/10.1161/circulationaha.125.078409
Vancouver
Algalarrondo V, Slama MS. Phase III ATTR-CM Trials: Rethinking the “Placebo” Arm. Circulation. 2026;153(10):693-695. doi:10.1161/circulationaha.125.078409
BibTeX
@article{Algalarrondo2026,
author = {Algalarrondo, Vincent and Slama, Michel S},
title = {Phase III ATTR-CM Trials: Rethinking the “Placebo” Arm},
journal = {Circulation},
year = {2026},
volume = {153},
number = {10},
pages = {693--695},
doi = {10.1161/circulationaha.125.078409}
}
EUVIMED